Loading
A phase 2 trial of HS-20089 in ovarian cancer and endometrial cancer, run by Hansoh BioMedical R&D Company, now recruiting.
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT06014190 by Hansoh BioMedical R&D Company, with 460 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20089. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares HS-20089, Hansoh Pharmaceutical, Ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares HS-20089, Endometrial cancer, Ovarian cancer.